Targeting tumor necrosis factor-α as a potential therapy in inflammatory skin diseases

Giampiero Girolomoni, Saveria Pastore, Cristina Albanesi, Andrea Cavani

Research output: Contribution to journalArticlepeer-review


Tumor necrosis factor-α (TNFα) plays an important role in the initiation and persistence of inflammation in a variety of skin disorders. The availability of selective TNFα blockers has provided new therapeutic opportunities. TNFα inhibitors have been employed with success in treating psoriasis in controlled trials, although further studies are warranted to better define which subgroup of patients can benefit most from this treatment and modalities of combination therapy. In addition, an increasing number of case reports indicates that anti-TNFα agents are of value in the treatment of other skin diseases, such a pyoderma gangrenosum and Behcet's syndrome, and in the treatment of graft-versus-host disease.

Original languageEnglish
Pages (from-to)1590-1595
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Issue number11
Publication statusPublished - Nov 1 2002


  • Etanercept
  • Inflammation
  • Infliximab
  • Psoriasis
  • TNFα

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Targeting tumor necrosis factor-α as a potential therapy in inflammatory skin diseases'. Together they form a unique fingerprint.

Cite this